Investment Analysts’ Recent Ratings Updates for Climb Bio (CLYM)

Climb Bio (NASDAQ: CLYM) has recently received a number of price target changes and ratings updates:

• 10/16/2025 – Climb Bio had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $8.00 price target on the stock.
• 10/16/2025 – Climb Bio is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 10/13/2025 – Climb Bio is now covered by analysts at HC Wainwright. They set a “buy” rating and a $9.00 price target on the stock.
• 10/13/2025 – Climb Bio is now covered by analysts at HC Wainwright. They set a “buy” rating and a $9.00 price target on the stock.
• 10/8/2025 – Climb Bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 10/6/2025 – Climb Bio was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.
• 9/30/2025 – Climb Bio had its price target raised by analysts at BTIG Research from $7.00 to $8.00. They now have a “buy” rating on the stock.
• 9/28/2025 – Climb Bio was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating.
• 9/27/2025 – Climb Bio had its “sell (d-)” rating reaffirmed by analysts at Weiss Ratings.
• 9/22/2025 – Climb Bio had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $7.00 price target on the stock.
• 9/20/2025 – Climb Bio was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating.

Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.